Assessment of bioartificial liver support in acute liver failure

International Journal of Artificial Organs

Volumn 19, Issue 1, 1996, Pages 3-6

  Hughes, R D ^a   Williams, R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LIVER FAILURE; BIOARTIFICIAL LIVER;

ARTIFICIAL ORGANS;

LIDOCAINE; N METHYLERYTHROMYCIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTIFICIAL LIVER; CONFERENCE PAPER; HUMAN; LIVER FAILURE; NONHUMAN;

EID: 0029872096     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889601900102     Document Type: Conference Paper

References (18)

1. Hughes RD, Williams R. Clinical experience with charcoal and resin haemoperfusion. Semin Liver Dis 1986; 6: 164-73.
2. Hughes RD, Williams R. Use of sorbent columns and haemofiltration in fulminant hepatic failure. Blood Purif 1993; 11: 163-9.
3. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186-92.
4. Nyberg SL, Shatford RA, Hu W-S, Payne WD, Cerra FB. Hepatocyte culture systems for artificial liver support: implications for critical care medicine (bioartificial liver support). Crit Care Med 1992; 20: 1157-68.
5. Jauregui HO, Gann KL. Mammalian hepatocytes as a foundation for treatment in human liver failure. J Cellular Biochem 1991; 45: 359-65.
6. Gerlach JC, Encke J, Hole O, Muller C, Courtney JM, Neuhaus P. Hepatocyte culture between three dimensionally arranged biomatrix-coated independent artificial capillary systems and sinusoidal endothelial cell coculture compartments. Int J Artif Organs 1994; 17: 301-6
7. Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16: 60-5.
8. Rozga J, Williams F, Ro M-S, et al. Develpment of a bioartificial liver: properties and function of a hollow-fibre module inoculated with liver cells. Hepatology 1993; 17: 258-65.
9. Sussman NL, Gislason G, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artificial Organs 1994; 18: 390-6.
10. Rozga J, Podesta L, LePage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 5: 538-46.
11. Ellis AJ, Wendon J, Hughes R, et al. A controlled trial of the Hepatix extracorporeal liver assist device (ELAD) in acute liver failure. Hepatology 1994; 20: 140A.
12. O'Grady JG, Alexander GL, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.
13. Ash SR, Blake DE, Carr DJ, Carter C, Howard T. Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15: 151-61.
14. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organ 1994; 17: 657-62.
15. Ozawa K, Aoyama H, Yasuda K, et al. Metabolic abnormalities associated with postoperative organ failure. A redox theory. Arch Surg 1983; 118: 1245-51.
16. Swain S, Butterworth RF, Blei AT. Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats. Hepatology 1992; 15: 449-53.
17. Hilgier W, Olson JE. Brain ion and amino acid contents during edema development in hepatic encephatopathy. J Neurochem 1994; 62: 197-204.
18. Hughes RD, Cochrane AMG, Thomson AD, Murray-Lyon IM, Williams R. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exper Path 1976; 57: 348-53.